North America CAR-T Cell Therapy Market Size, Share, By Drug Type (Ciloleucel, Axicabtagene, Brexucabtagene Autoleucel, Tisagenlecleucel, and Others), By Indication (Acute Lymphocyctic Leukemia, Lymphoma, Non-Hodgkin Leukemia and Others), By End-Users (Hospitals, Cancer Research Centers, and Others) and By Country - Trends, Analysis and Forecast till 2034

Report Code: PMI541924 | Publish Date: July 2024 | No. of Pages: 132

North America Car T Cell Therapy Market Overview

North America CAR-T Cell Therapy Market was valued at USD 2.05 Billion in 2024 and is expected to reach USD 10.9 Billion by 2034 growing at a CAGR of 1.9%

The CAR-T cell therapy market in North America is experiencing substantial growth, driven by significant advancements in biotechnology and a concerted focus on developing innovative cancer treatments. CAR-T cell therapy, which involves engineering a patient’s T-cells to specifically target and destroy cancer cells, has demonstrated considerable efficacy, particularly in treating hematologic malignancies such as leukemia and lymphoma. This revolutionary approach is transforming the landscape of cancer treatment in the region.

North America Car T Cell Therapy Market Dynamics

Key Drivers of Target Market:

Robust Research and Development Infrastructure

North America, especially the United States, boasts a strong foundation of leading research institutions, universities, and biotech companies that are pioneering the development of CAR-T cell therapies. Substantial investments in research and development from both public and private sectors have accelerated the innovation and commercialization of these therapies. Collaborative efforts between academia, industry, and government entities have resulted in a thriving ecosystem conducive to groundbreaking advancements in CAR-T cell therapy.

High Prevalence of Cancer

The high incidence of various cancers in North America underscores the urgent need for effective treatment options. CAR-T cell therapy provides a promising solution for patients who have not responded to conventional treatments. The substantial patient population seeking advanced therapies has created a significant demand for CAR-T cell therapy, thereby driving market growth. The region’s healthcare providers are increasingly adopting these therapies to improve patient outcomes, further fueling market expansion.

Restrains:

High Treatment Costs

Despite the potential of CAR-T cell therapy to revolutionize cancer treatment, the high cost associated with these therapies remains a significant barrier. The personalized nature of CAR-T cell therapy involves complex manufacturing processes and extensive clinical oversight, leading to substantial expenses. These high costs can make the therapy inaccessible for many patients, limiting its widespread adoption. Efforts to reduce costs through technological advancements and economies of scale are ongoing, but the financial burden remains a key challenge in the market.

North America Car T Cell Therapy Market Segmentation

The market is segmented based on Drug Type, Indication, End-User and Country.

North America CAR-T Cell Therapy Market Report Scope:

Attribute

Details

Market Size 2024

USD 2.05 Billion

Projected Market Size 2034

USD 10.9 Billion

CAGR Growth Rate

1.9%

Base year for estimation

2023

Forecast period

2024 – 2034

Market representation

Revenue in USD Billion & CAGR from 2024 to 2034

Market Segmentation

By Drug Type - Ciloleucel, Axicabtagene, Brexucabtagene Autoleucel, Tisagenlecleucel, and Others

By Indication - Acute Lymphocyctic Leukemia, Lymphoma, Non-Hodgkin Leukemia and Others

By End User - Hospitals, Cancer Research Centers, and Others

Report coverage

Revenue forecast, company share, competitive landscape, growth factors, and trends

Segments Covered in the Report:

This report forecasts revenue growth at regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2023 to 2034. For the purpose of this study, has segmented the North America CAR-T Cell Therapy Market report based on Drug Type, Indication, End User and Country:

Segmentation:

By Drug Type:

  • Ciloleucel
  • Axicabtagene
  • Brexucabtagene Autoleucel
  • Tisagenlecleucel
  • Others    

By Indication:

  • Acute Lymphocyctic Leukemia
  • Lymphoma
  • Non-Hodgkin Leukemia
  • Others

By End User:

  • Hospitals
  • Cancer Research Centers
  • Others

By Country:

  • U.S.
  • Canada

North America Car T Cell Therapy Market Key Players

The key players operating the North America CAR-T Cell Therapy Market includes, Bristol Myer Squibb, MERCK & CO. INC., PFIZER INC., Bluebird Bio-Inc., Novartis AG, Caribou Biosciences Inc., CELGENE CORPORATION, Sorrento Therapeutics Inc.

North America Car T Cell Therapy Market Company Profile

  • Bristol Myer Squibb, Inc. *
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Business Strategies
  • MERCK & CO. INC.
  • PFIZER INC.
  • Bluebird Bio-Inc.
  • Novartis AG
  • Caribou Biosciences Inc.
  • CELGENE CORPORATION, INC.
  • Sorrento Therapeutics Inc.

“*” marked represents similar segmentation in other categories in the respective section.

North America Car T Cell Therapy Market Table of Contents

Research Objective and Assumption

  • Research Objectives
  • Assumptions
  • Abbreviations

Market Preview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Market Snippet, By Drug Type
    • Market Snippet, By Indication
    • Market Snippet, By End User
    • Market Snippet, By Country
  • Opportunity Map Analysis

Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
    • Drivers
    • Restraints
    • Market Opportunities
  • Market Trends
  • Product Launch
  • Merger and Acquisitions
  • Impact Analysis
  • PEST Analysis
  • Porter’s Analysis

Market Segmentation, By Drug Type, Forecast Period up to 10 Years, (USD Bn)

  • Overview
    • Market Value and Forecast (USD Bn), and Share Analysis (%), Forecast Period up to 10 Years
    • Y-o-Y Growth Analysis (%), Forecast Period up to 10 Years
    • Segment Trends
  • Ciloleucel
    • Overview
    • Market Size and Forecast (USD Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
  • Axicabtagene
    • Overview
    • Market Size and Forecast (USD Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
  • Brexucabtagene Autoleucel
    • Overview
    • Market Size and Forecast (USD Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
  • Tisagenlecleucel
    • Overview
    • Market Size and Forecast (USD Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
  • Others
    • Overview
    • Market Size and Forecast (USD Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years

Market Segmentation, Indication, Forecast Period up to 10 Years, (USD Bn)

  • Overview
    • Market Value and Forecast (USD Bn), and Share Analysis (%), Forecast Period up to 10 Years
    • Y-o-Y Growth Analysis (%), Forecast Period up to 10 Years
    • Segment Trends
  • Acute Lymphocyctic Leukemia
    • Overview
    • Market Size and Forecast (USD Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
  • Lymphoma
    • Overview
    • Market Size and Forecast (USD Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
  • Non-Hodgkin Leukemia
    • Overview

Market Size and Forecast (USD Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years

  • Others
    • Overview

Market Size and Forecast (USD Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years

Market Segmentation, End User, Forecast Period up to 10 Years, (USD Bn)

  • Overview
    • Market Value and Forecast (USD Bn), and Share Analysis (%), Forecast Period up to 10 Years
    • Y-o-Y Growth Analysis (%), Forecast Period up to 10 Years
    • Segment Trends
  • Hospitals
    • Overview
    • Market Size and Forecast (USD Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
  • Cancer Research Centers
    • Overview
    • Market Size and Forecast (USD Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
  • Others
    • Overview
    • Market Size and Forecast (USD Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years

Market Segmentation, By Country, Forecast Period up to 10 Years, (USD Bn)

  • Overview
    • Market Value and Forecast (USD Bn), and Share Analysis (%), Forecast Period up to 10 Years
    • Y-o-Y Growth Analysis (%), Forecast Period up to 10 Years
    • Country Trends
  • North America
    • Market Size and Forecast (USD Bn), By Drug Type, Forecast Period up to 10 Years
    • Market Size and Forecast (USD Bn), By Indication, Forecast Period up to 10 Years
    • Market Size and Forecast (USD Bn), By End User, Forecast Period up to 10 Years
    • Market Size and Forecast (USD Bn), By Country, Forecast Period up to 10 Years
      • U.S.
      • Canada

Competitive Landscape

  • Heat Map Analysis
  • Company Profiles
    • Bristol Myer Squibb
    • MERCK & CO. INC.
    • PFIZER INC.
    • Bluebird Bio-Inc.
    • Novartis AG
    • Caribou Biosciences Inc.
    • CELGENE CORPORATION, Inc.
    • Sorrento Therapeutics Inc.

The Last Word

  • Future Impact
  • About Us
  • Contact

FAQs

The North America CAR-T Cell Therapy Market is segmented into Drug Type, Indication, End User and Country.

Robust Research and Development Infrastructure and High Prevalence of Cancer.

By Country, the North America CAR-T Cell Therapy Market is segmented into U.S. and Canada, U.S is expected to dominate the Market due to increase in Investment in Research.

The key players operating the North America CAR-T Cell Therapy Market includes, Bristol Myer Squibb, MERCK & CO. INC., PFIZER INC., Bluebird Bio-Inc., Novartis AG, Caribou Biosciences Inc., CELGENE CORPORATION, INC., Sorrento Therapeutics Inc.